This Article Full Text Full Text (PDF) All Versions of this Article: 93/1/68    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laughlin, G. A. Articles by Bergstrom, J. Search for Related Content PubMed PubMed Citation Articles by Laughlin, G. A. Articles by Bergstrom, J. Related Collections Male Endocrinology

Low Serum Testosterone and Mortality in Older Men

Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093

Address all correspondence and requests for reprints to: Gail A. Laughlin, Ph.D., Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0631C, La Jolla, California 92093. E-mail: glaughlin{at}ucsd.edu.

Context: Declining testosterone levels in elderly men are thought to underlie many of the symptoms and diseases of aging; however, studies demonstrating associations of low testosterone with clinical outcomes are few.

Objective: The objective of the study was to examine the association of endogenous testosterone levels with mortality in older community-dwelling men.

Design, Setting, and Participants: This was a prospective, population-based study of 794 men, aged 50–91 (median 73.6) yr who had serum testosterone measurements at baseline (1984–1987) and were followed for mortality through July 2004.

Main Outcome Measure: All-cause mortality by serum testosterone level was measured.

Results: During an average 11.8-yr follow-up, 538 deaths occurred. Men whose total testosterone levels were in the lowest quartile (<241 ng/dl) were 40% [hazards ratio (HR) 1.40; 95% confidence interval (CI) 1.14–1.71] more likely to die than those with higher levels, independent of age, adiposity, and lifestyle. Additional adjustment for health status markers, lipids, lipoproteins, blood pressure, glycemia, adipocytokines, and estradiol levels had minimal effect on results. The low testosterone-mortality association was also independent of the metabolic syndrome, diabetes, and prevalent cardiovascular disease but was attenuated by adjustment for IL-6 and C-reactive protein. In cause-specific analyses, low testosterone predicted increased risk of cardiovascular (HR 1.38; 95% CI 1.02–1.85) and respiratory disease (HR 2.29; 95% CI 1.25–4.20) mortality but was not significantly related to cancer death (HR 1.34; 95% CI 0.89–2.00). Results were similar for bioavailable testosterone.

Conclusions: Testosterone insufficiency in older men is associated with increased risk of death over the following 20 yr, independent of multiple risk factors and several preexisting health conditions.

This article has been cited by other articles:

				I. Peter, A. Kelley-Hedgepeth, C. S. Fox, L. Adrienne Cupples, G. S. Huggins, D. E. Housman, R. H. Karas, M. E. Mendelsohn, D. Levy, and J. M. Murabito Variation in Estrogen-Related Genes Associated with Cardiovascular Phenotypes and Circulating Estradiol, Testosterone, and Dehydroepiandrosterone Sulfate Levels J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2779 - 2785. [Abstract] [Full Text] [PDF]

				E. A. Platz Low Testosterone and Risk of Premature Death in Older Men: Analytical and Preanalytical Issues in Measuring Circulating Testosterone Clin. Chem., July 1, 2008; 54(7): 1110 - 1112. [Full Text] [PDF]